术前前列腺特异性膜抗原正电子发射断层扫描阴性前列腺癌患者盆腔淋巴结清扫候选者列线图的外部验证
这项多中心外部验证纳入2016至2023年间10个中心282例术前PSMA PET阴性(miN0)的中高危前列腺癌患者,均接受根治性前列腺切除术及扩大盆腔淋巴结清扫。总体淋巴结侵犯率为13%(36例)。Briganti 2023列线图的C指数为77%,高于其他列线图,采用5%阈值可避免47%的ePLND手术,仅漏诊5例(3.8%)淋巴结侵犯。
要点
- Briganti 2023列线图C指数77%,高于MSKCC、Briganti 2017/2019及Amsterdam-Brisbane-Sydney列线图。
- Briganti 2023列线图净获益更高,5%阈值可避免47%的ePLND,仅漏诊5例(3.8%)淋巴结侵犯。
- 患者选择和影像方案异质性是该研究的主要局限性。
核心结论
- Briganti 2023列线图在预测miN0前列腺癌患者淋巴结侵犯方面优于其他可用工具。
- 使用该工具在当代临床环境中避免了相当数量的不必要ePLND手术,并优化了ePLND推荐。
研究设计与样本
- 外部验证研究,纳入2016至2023年间10个中心282例接受根治性前列腺切除术及扩大盆腔淋巴结清扫的miN0中高危前列腺癌患者。
- 采用校准图、C指数和决策曲线分析评估MSKCC、Amsterdam-Brisbane-Sydney及Briganti 2017、2019、2023列线图的校准度、区分度和净获益。
主要发现
- 总体36例(13%)患者存在淋巴结侵犯。
- MSKCC、Briganti 2017、Briganti 2019、Amsterdam-Brisbane-Sydney和Briganti 2023列线图的C指数分别为64%、69%、72%、64%和77%。
- Briganti 2023列线图净获益高于其他列线图。
- 采用5%阈值时,Briganti 2023列线图可避免47%的ePLND手术,Briganti 2019和Amsterdam-Brisbane-Sydney列线图分别避免14%和4.3%,代价为仅漏诊5例(3.8%)淋巴结侵犯。
关键数值与推荐
- Briganti 2023列线图C指数为77%。
- Briganti 2023列线图采用5%阈值可避免47%的ePLND手术,仅漏诊5例(3.8%)淋巴结侵犯。
临床怎么用
- 原文未据此给出推荐。
局限性
- 患者选择异质性。
- 影像方案异质性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Extended pelvic lymph node dissection (ePLND) is recommended in selected radical prostatectomy (RP) prostate cancer (PCa) patients for staging purposes. We aim to externally validate available tools to predict lymph node invasion (LNI) in men with negative preoperative prostate-specific membrane antigen positron emission tomography (miN0). METHODS: Overall, 282 intermediate- to high-risk PCa patients with miN0 disease undergoing RP and ePLND at ten centers between 2016 and 2023 were identified. The Memorial Sloan Kettering Cancer Center (MSKCC); Amsterdam-Brisbane-Sydney; and Briganti 2017, 2019, and 2023 tools predicting LNI were validated externally using calibration plots, C-indexes, and decision-curve analyses to assess calibration, discrimination, and net benefit. KEY FINDINGS AND LIMITATIONS: Overall, 36 (13%) patients had LNI. The C-indexes of the MSKCC, Briganti 2017, Briganti 2019, Amsterdam-Brisbane-Sydney, and Briganti 2023 nomograms were 64%, 69%, 72%, 64%, and 77%, respectively. The Briganti 2023 nomogram exhibited higher net benefit than the other available nomograms, and the use of a 5% cutoff would have spared 47% ePLND procedures (vs 14% and 4.3% for the Briganti 2019 and Amsterdam-Brisbane-Sydney nomograms, respectively) at the cost of missing only five (3.8%) LNI cases. Heterogeneity in patient selection and imaging protocols represents the main limitations. CONCLUSIONS AND CLINICAL IMPLICATIONS: The Briganti 2023 nomogram outperformed other available tools in predicting LNI in men with miN0 PCa. The use of this tool resulted in a considerable number of unnecessary ePLND procedures spared and optimization of ePLND recommendations in a contemporary clinical setting.
引用
- Gandaglia G, Barletta F, Scuderi S, et al. External Validation of Nomograms for the Identification of Pelvic Nodal Dissection Candidates Among Prostate Cancer Patients with Negative Preoperative Prostate-specific Membrane Antigen Positron Emission Tomography. Eur Urol Oncol. 2025. PMID: 39890547. doi:10.1016/j.euo.2025.01.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。